See every side of every news story
Published loading...Updated

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

  • Kodiak Sciences Inc. Announced the completion of enrollment in the GLOW2 Phase 3 trial for tarcocimab in diabetic retinopathy patients.
  • The study design of GLOW2 mirrors the successful GLOW1 study, which met its primary endpoint with high statistical significance.
  • Dr. Victor Perlroth stated that topline clinical data is expected to be announced in the first quarter of 2026 after all patients complete visits by January 2026.
  • Dr. Hu emphasized that tarcocimab could change the treatment landscape for diabetic retinopathy, helping millions of patients with its less frequent dosing.
Insights by Ground AI
Does this summary seem wrong?

24 Articles

All
Left
1
Center
9
Right
1
Helena Independent RecordHelena Independent Record
+22 Reposted by 22 other sources
Center

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026.GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significance

·Helena, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 82% of the sources are Center
82% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Helena Independent Record broke the news in Helena, United States on Monday, March 10, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.